Preclinical investigations have suggested that breast cancer cells exhibiting reduced INPP4B expression may display heightened sensitivity to selective inhibitors of the PI3K pathway, presenting a promising avenue for targeted therapeutic strategies [72]. This evidence concerns the gene PIK3CD and breast cancer.